Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 197-204, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vestergaard, E. M.
Right arrow Articles by Ørntoft, T. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vestergaard, E. M.
Right arrow Articles by Ørntoft, T. F.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 1998;44:197-204.)
© 1998 American Association for Clinical Chemistry, Inc.

Enzymes and Protein Markers

Increased concentrations of genotype-interpreted Ca 19-9 in urine of bladder cancer patients mark diffuse atypia of the urothelium

Else Marie Vestergaard1,2, Hans Wolf2, and Torben F. Ørntoft1,a

Departments of
1 Clinical Biochemistry and
2 Urology, Skejby University Hospital, DK 8200 Aarhus N, Denmark.
a Author for correspondence. Fax 45 89 49 60 18; e-mail orntoft{at}kba.sks.aau.dk.

We investigated the use of genotype-interpreted measurements of the tumor marker Ca 19-9 in the urine of bladder cancer patients as a marker of the extent of urothelial disease. Ca 19-9 in urine (sialyl-Lea/creatinine ratio) was measured in 81 bladder cancer patients and correlated to T-category, histologic grade, and presence of urothelial dysplasia. As reference group, Ca 19-9 ratio was measured in urine from 21 apparently healthy individuals. The amount of sialyl-Lea expressed is influenced by the Lewis genotype and secretor status. Accordingly, secretor status was determined in urine by a novel ELISA method, and the Lewis genotypes of all of the individuals were determined by PCR cleavage methods. Ca 19-9 concentrations in urine were higher (P <0.01) in bladder cancer patients than in healthy individuals and significantly (P =0.02) higher in cancer patients with concomitant urothelial dysplasia than in those with normal urothelium. For individuals Lewis-genotyped as homozygous wild-type, Ca 19-9 concentrations in urine were higher, both in cancer patients (P = 0.06) and in healthy individuals (P = 0.004), than in the heterozygous individuals. Furthermore, nonsecretor cancer patients had higher (P <0.01) Ca 19-9 concentrations in urine. Attention is drawn to the possibility of a general genotype interpretation of a result in clinical chemistry.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
E. M. Vestergaard, H. O. Hein, H. Meyer, N. Grunnet, J. Jorgensen, H. Wolf, and T. F. Orntoft
Reference Values and Biological Variation for Tumor Marker CA 19-9 in Serum for Different Lewis and Secretor Genotypes and Evaluation of Secretor and Lewis Genotyping in a Caucasian Population
Clin. Chem., January 1, 1999; 45(1): 54 - 61.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.